DOI: https://doi.org/10.24959/ophcj.19.174807

The search for potential inhibitors of protein kinase Pim-1 among new amides of 1,2,4-triazolo[4,3-a]pyridine-3-metanamin with the 1,2,4-oxadiazol cycle in position 7 and 8

V. R. Karpina, S. M. Kovalenko, O. V. Zaremba, O. V. Silin, V. V. Ivanov, S. S. Kovalenko, T. Langer

Abstract


The Pim-1 enzyme from the serine/threonine protein kinase family is a likely target for the targeted therapy of tumors of hematopoietic and lymphoid tissues. Triazolopyridine is an universal scaffold upon which international scientific programs have been launched to develop potential anticancer agents.
Aim. To create a pharmacophore model to find new potential Pim-1 inhibitors; conduct a virtual screening of a simulated base of new 1,2,4-triazolo[4,3-a]pyridine derivatives; develop a method for the synthesis of 1,2,4-triazolo[4,3-a]pyridine-3-methanamines with the 1,2,4-isoxadiazole cycle.
Results and discussion. In this study, a ligand-based pharmacophore model for Pim-1 inhibitors was constructed and validated. A virtual screening of the library with 912 compounds resulted in a hit list of 175 compounds. For the synthesis, 15 compounds were selected with the highest pharmacophore-fit score. 15 compounds were synthesized as potential inhibitors of Pim-1 kinase.
Experimental part. The synthetic approach has been developed, and systematic series of new amides of (7-(1,2,4-oxadiazol-5-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl)methanamine and (8-(1,2,4-oxadiazol-5-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl)methanamine have been synthesized.
Conclusions. The compounds obtained are potential inhibitors of Pim-1 kinase. Further studies will focus on the determination of the antitumor activity of the compounds synthesized by in vitro and in vivo methods.

Keywords


1,2,4-triazolo[4,3-a]pyridine; 1,2,4-oxadiazole; Pim-1 protein kinase; antitumor activity; pharmacophore model; virtual screening

References


Cancer Facts and Figures. American Cancer Society. (2016). Available at: https://www.cancer.org/content/dam/cancer-org/research/cancerfacts-and-statistics/annual-cancer-facts-and-figures/2016/cancer-facts-and-figures-2016.pdf

World Health Organization (WHO), Cancer key facts. (2017). Available at: https://www.who.int/cancer/media/news/cancer-key-facts/en/3. Nakhjiri, M., Safavi, M., Alipour, E., Emami, S., Atash, A. F., Jafari-Zavareh, M., … Shafiee, A. (2012). Asymmetrical 2,6-bis(benzylidene)cyclohexanones: Synthesis, cytotoxic activity and QSAR study. European Journal of Medicinal Chemistry, 50, 113–123. https://doi.org/10.1016/j.ejmech.2012.01.045

Ananda Kumar, C. S., Nanjunda Swamy, S., Thimmegowda, N. R., Benaka Prasad, S. B., Yip, G. W., Rangappa, K. S. (2007). Synthesis and evaluation of 1-benzhydryl-sulfonyl-piperazine derivatives as inhibitors of MDA-MB-231 human breast cancer cell proliferation. Medicinal Chemistry Research, 16 (4), 179–187. https://doi.org/10.1007/s00044-007-9022-y

Bachmann, M., Möröy, T. (2005). The serine/threonine kinase Pim-1. The International Journal of Biochemistry & Cell Biology, 37 (4), 726–730. https://doi.org/10.1016/j.biocel.2004.11.005

Hsi, E. D., Jung, S.-H., Lai, R., Johnson, J. L., Cook, J. R., Jones, D., … Said, J. (2008). Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia Group B 59909 correlative science study. Leukemia & Lymphoma, 49 (11), 2081–2090. https://doi.org/10.1080/10428190802419640

Amson, R., Sigaux, F., Przedborski, S., Flandrin, G., Givol, D., Telerman, A. (1989). The human protooncogene product p33pim is expressed during fetal hematopoiesis and in diverse leukemias. Proceedings of the National Academy of Sciences, 86 (22), 8857–8861. https://doi.org/10.1073/pnas.86.22.8857

Valdman, A., Fang, X., Pang, S.-T., Ekman, P., Egevad, L. (2004). Pim-1 expression in prostatic intraepithelial neoplasia and human prostate cancer. The Prostate, 60 (4), 367–371. https://doi.org/10.1002/pros.20064

Beier, U., Weise, J., Laudien, M., Sauerwein, H., Görögh, T. (2007). Overexpression of Pim-1 in head and neck squamous cell carcinomas. International Journal of Oncology, 30, 1381–1387. https://doi.org/10.3892/ijo.30.6.1381

Babel, I., Barderas, R., Díaz-Uriarte, R., Martínez-Torrecuadrada, J. L., Sánchez-Carbayo, M., Casal, J. I. (2009). Identification of Tumor-associated Autoantigens for the Diagnosis of Colorectal Cancer in Serum Using High Density Protein Microarrays. Molecular & Cellular Proteomics, 8 (10), 2382–2395. https://doi.org/10.1074/mcp.m800596-mcp200

Arunesh, G. M., Shanthi, E., Krishna, M. H., Sooriya Kumar, J., Viswanadhan, V. N. (2013). Small molecule inhibitors of PIM1 kinase: July 2009 to February 2013 patent update. Expert Opinion on Therapeutic Patents, 24 (1), 5–17. https://doi.org/10.1517/13543776.2014.848196

Blanco-Aparicio, C., Collazo, A. M. G., Oyarzabal, J., Leal, J. F., Albarán, M. I., Lima, F. R., … Bischoff, J. R. (2011). Pim 1 kinase inhibitor ETP-45299 suppresses cellular proliferation and synergizes with PI3K inhibition. Cancer Letters, 300 (2), 145–153. https://doi.org/10.1016/j.canlet.2010.09.016

Karpina, V. R., Kovalenko, S. S., Kovalenko, S. M., Zaremba, O. V., Silin, O. V., Langer, T. (2019). The synthesis and biological assessment of [[1,2,4]triazolo[4,3-a]pyridine-3-yl]acetamides with an 1,2,4-oxadiazol cycle in positions 6, 7 and 8. Journal of Organic and Pharmaceutical Chemistry, 17 (65), 28–35. https://doi.org/10.24959/ophcj.19.965

Patent WO004984. (2013). Tricyclic compounds for use as kinase inhibitors. Centro Nacional de Investigaciones Oncologicas (CNIO).

Patent WO022076. (2010). Triazolopyridine compounds as PIM kinase inhibitors. Array Biopharma, Inc.

Patent WO022081. (2010). Triazolopyridine compounds as PIM kinase inhibitors. Array Biopharma, Inc.

Duanmu, C., Shahrik, L. K., Ho, H. H., Hamel, E. (1989). Tubulin-dependent hydrolysis of Guanosine Triphosphate as a screening test to identify new antitubulin compounds with potential as antimitotic agents: application to carbamates of aromatic amines. Cancer Research, 49, 1344–1348.

Shahzad, S. A., Yar, M., Bajda, M., Jadoon, B., Khan, Z. A., Naqvi, S. A. R., … Filipek, S. (2014). Synthesis and biological evaluation of novel oxadiazole derivatives: A new class of thymidine phosphorylase inhibitors as potential anti-tumor agents. Bioorganic & Medicinal Chemistry, 22 (3), 1008–1015. https://doi.org/10.1016/j.bmc.2013.12.043

Kemnitzer, W., Kuemmerle, J., Zhang, H.-Z., Kasibhatla, S., Tseng, B., Drewe, J., Cai, S. X. (2009). Discovery of 3-aryl-5-aryl-1,2,4-oxadiazoles as a new series of apoptosis inducers. 2. Identification of more aqueous soluble analogs as potential anticancer agents. Bioorganic & Medicinal Chemistry Letters, 19 (15), 4410–4415. https://doi.org/10.1016/j.bmcl.2009.05.052

El-Garhy, O. H. (2015). An overview of the azoles of interest. International Journal of Current Pharmaceutical Research, 7 (1), 1–6.

Wermuth, C. G., Ganellin, C. R., Lindberg, P., Mitscher, L. A. (1998). Glossary of terms used in medicinal chemistry (IUPAC Recommendations). Pure and Applied Chemistry, 70, 1129−1143. https://doi.org/10.1515/iupac.70.0050

Gao, Q., Yang, L., Zhu, Y. (2010). Pharmacophore Based Drug Design Approach as a Practical Process in Drug Discovery. Current Computer Aided-Drug Design, 6 (1), 37–49. https://doi.org/10.2174/157340910790980151

Mysinger, M. M., Carchia, M., Irwin, J. J., & Shoichet, B. K. (2012). Directory of Useful Decoys, Enhanced (DUD-E): Better Ligands and Decoys for Better Benchmarking. Journal of Medicinal Chemistry, 55 (14), 6582–6594. https://doi.org/10.1021/jm300687e

Sterling, T., Irwin, J. J. (2015). ZINC 15 – Ligand Discovery for Everyone. Journal of Chemical Information and Modeling, 55 (11), 2324–2337. https://doi.org/10.1021/acs.jcim.5b00559

Wolber, G., Langer, T. (2005). Ligand Scout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters. Journal of Chemical Information and Modeling, 45, 160–169.

Wolber, G., Dornhofer, A. A., & Langer, T. (2006). Efficient overlay of small organic molecules using 3D pharmacophores. Journal of Computer-Aided Molecular Design, 20(12), 773–788. https://doi.org/10.1007/s10822-006-9078-7

Wolber, G., Seidel, T., Bendix, F., Langer, T. (2008). Molecule pharmacophore super positioning and pattern matching in computational drug design. Drug Discovery Today, 13, 23–29.

Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001). Experimental and computational approaches to estimate solubility and permeabilityy in drug discovery and development settings. Adv. Drug Delivery Rev., 46, 3−26. https://doi.org/10.1016/s0169-409x(00)00129-0

Daina, A., Michielin, O., & Zoete, V. (2019). SwissTargetPrediction: updated data and new features for efficient prediction of protein targets of small molecules. Nucleic Acids Research, 47(W1), W357–W364. https://doi.org/10.1093/nar/gkz382


GOST Style Citations


1. Cancer Facts and Figures. American Cancer Society. – 2016. [Електронний ресурс]. – Режим доступу : https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2016/cancer-facts-and-figures-2016.pdf


2. World Health Organization (WHO), Cancer key facts. – 2017. [Електронний ресурс]. – Режим доступу : https://www.who.int/cancer/media/news/cancer-key-facts/en/


3. Asymmetrical 2,6-bis(benzylidene)cyclohexanones : Synthesis, cytotoxic activity and QSAR study / M. Nakhjiri, M. Safavi, E. Alipour et al. // Eur. J. Med. Chem. – 2012. – Vol. 50. – P. 113–123. https://doi.org/10.1016/j.ejmech.2012.01.045


4. Synthesis and evaluation of 1-benzhydryl-sulfonyl-piperazine derivatives as inhibitors of MDA-MB-231 human breast cancer cell proliferation /C. S. A. Kumar, S. N. Swamy, N. R. Thimmegowda et al. // Med. Chem. Res. – 2007. – P. 179–187. https://doi.org/10.1007/s00044-007-9022-y


5. Bachmann, M. The serine/ threonine kinase Pim-1 / M. Bachmann, T. Moroy // International Journal of Biochemistry and Cell Biology. – 2005. – Vol. 37, Issue 4. – P. 726–730. https://doi.org/10.1016/j.biocel.2004.11.005


6. Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab : a Cancer and Leukemia Group B 59909 correlative science study / E. D. His, S. H. Jung, R. Lai et al. // Leuk. Lymphoma. – 2008. – Vol. 49. – P. 2081–2090. https://doi.org/10.1080/10428190802419640


7. The human protooncogene product p33pim is expressed during fetal hematopoiesis and in diverse leukemias / R. Amson, F. Sigaux, S. Przedborski et al. // Proc. Natl. Acad. Sci. USA. – 1989. – Vol. 86. – P. 8857–8861. https://doi.org/10.1073/pnas.86.22.8857


8. Pim-1 expression in prostatic intraepithelial neoplasia and human prostate cancer / A. Valdman, X. Fang, S. T. Pang et al. // Prostate. – 2004. – Vol. 60. – P. 367–371. https://doi.org/10.1002/pros.20064


9. Overexpression of Pim-1 in head and neck squamous cell carcinomas / U. H. Beier, J. B. Weise, M. Laudien et al. // Int. J. Oncol. – 2007. – Vol. 30. – P. 1381–1387. https://doi.org/10.3892/ijo.30.6.1381


10. Identification of tumorassociated autoantigens for the diagnosis of colorectal cancer in serum using high density protein microarrays / I. Babel, R. Barderas, R. Diaz-Uriarte et al. // Mol. Cell Proteomics. – 2009. – Vol. 8. – P. 2382–2395. https://doi.org/10.1074/mcp.m800596-mcp200


11. Small molecule inhibitors of PIM1 kinase : July 2009 to February 2013 patent update / G. M. Arunesh, E. Shanthi, M. H. Krishna et al. // Expert Opin. Ther. Patents. – 2014. – Vol. 24, Issue 1. https://doi.org/10.1517/13543776.2014.848196


12. Pim 1 Kinase Inhibitor ETP-45299 Suppresses Cellular Proliferation and Synergizes with PI3K Inhibition / C. Blanco-Aparicio, A. M. G. Collazo, J. Oyarzabal et al. // Cancer Lett. – 2011. – Vol. 300. – P. 145–153. https://doi.org/10.1016/j.canlet.2010.09.016


13. The synthesis and biological assessment of [[1,2,4]triazolo[4,3-a]pyridine-3-yl]acetamides with an 1,2,4-oxadiazol cycle in positions 6, 7 and 8 / V. R. Karpina, S. S. Kovalenko, S. M. Kovalenko et al. // Журн. орг. та фармац. хімії. – 2019. – Т. 17, вип. 1 (65). https://doi.org/10.24959/ophcj.19.965


14. Patent CA2786002A1. 2013. Centro Nacional de Investigaciones Oncologicas (CNIO). Tricyclic compounds for use as kinase inhibitors // Canada WO004984 / Fernandez J. P., Aparicio C. B., Hergueta A. R. et al.


15. Patent C07D 471/04 (2006.01) A61K 31/47 (2006.01). Triazolopyridine compounds as PIM kinase inhibitors. WO022076. 2010. // Array Biopharma, Inc.


16. Patent Triazolopyridine compounds as PIM kinase inhibitors. WO022081. 2010. // Array Biopharma, Inc.


17. Tubulin-dependent hydrolysis of Guanosine Triphosphate as a screening test to identify new antitubulin compounds with potential as antimitotic agents : application to carbamates of aromatic amines / C. Duanmu, L. K. Shahrik, H. H. Ho, E. Hamel // Cancer Research. – 1989. – Vol. 49. – P. 1344–1348.


18. Synthesis and biological evaluation of novel oxadiazole derivatives : a new class of thymidine phosphorylase inhibitors as potential anti-tumor agents / S. A. Shahzad, M. Yar, M. Badja et al. // Bioorg. Med. Chem. – 2014. – Vol. 22. – P. 1008–1015. https://doi.org/10.1016/j.bmc.2013.12.043


19. Discovery of 3-aryl-5-aryl-1,2,4-oxadiazoles as a new series of apoptosis inducers. 2. Identification of more aqueous soluble analogs as potential anticancer agents / W. Kemnitzer, J. Kuemmerle, H. Z. Zhang et al. // Bioorg. Med. Chem. Lett. – 2009. – Vol. 19. – P. 4410–4415. https://doi.org/10.1016/j.bmcl.2009.05.052


20. El-Garhy, O. H.An overview of the azoles of interest / O. H. El-Garhy// Int. J. Curr. Pharm. Res. – 2015. – Vol. 7, Issue 1. – P. 1–6.


21. Glossary of terms used in medicinal chemistry (IUPAC Recommendations) / C. G. Wermuth, C. R. Ganellin, P. Lindberg et al. // Pure Appl. Chem. – 1998. – Vol. 70. – P. 1129−1143. https://doi.org/10.1515/iupac.70.0050


22. Gao, L. Pharmacophore based drug design approach as a practical process in drug discovery / Q. Gao, L. Yang, Y. Zhu // Curr. Comput.-Aided Drug Des. – 2010. – Vol. 6. – P. 37−49. https://doi.org/10.2174/157340910790980151


23. Directory of useful decoys, enhanced (DUD-E) : better ligands and decoys for better benchmarking / M. Mysinger, M. Carchia, J. Irwin et al. // Med. Chem. – 2012. – Vol. 55 (14). – P. 6582–6594. https://doi.org/10.1021/jm300687e


24. Sterling, T. ZINC 15 – Ligand Discovery for Everyone / T. Sterling, J. J. Irwin // J. Chem. Inf. Model. – 2015. – Vol. 55, Issue 11. – P. 2324–2337. https://doi.org/10.1021/acs.jcim.5b00559


25. Wolber, G. Ligand Scout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters / G. Wolber, T. Langer // J. Chem. Inf. Model. – 2005. – Vol. 45. – P. 160–169.


26. Wolber, G. Efficient overlay of small organic molecules using 3D pharmacophores / G. Wolber, A. A. Dornhofer, T. Langer // J. Comput. Aided Mol. Des. – 2006. – Vol. 20, Issue. 12. – P. 773–788. https://doi.org/10.1007/s10822-006-9078-7


27. Wolber, G. Molecule pharmacophore super positioning and pattern matching in computational drug design / G. Wolber, T. Seidel, F. Bendix // Drug Discov Today. – 2008. – Vol. 13. – P. 23–29.


28. Experimental and computational approaches to estimate solubility and permeabilityy in drug discovery and development settings / C. A. Lipinski, F. Lombardo, B. W. Dominy et al. // Adv. Drug Delivery Rev. – 2001. – Vol. 46. – P. 3−26. https://doi.org/10.1016/s0169-409x(00)00129-0


29. Daina, A. SwissTargetPrediction : updated data and new features for efficient prediction of protein targets of small molecules / A. Daina, O. Michielin, V. Zoete // Nucleic Acids Research. – 2019. – Vol. 47, Issue W1. – P. W357–W364. https://doi.org/10.1093/nar/gkz382





Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Abbreviated key title: J. Org. Pharm. Chem.

ISSN 2518-1548 (Online), ISSN 2308-8303 (Print)